Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population

Mojumdar, Kamalika; Vajpayee, Madhu; Chauhan, Neeraj K.; Mendiratta, Sanjay
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p416
Academic Journal
Background: Timely access to antiretroviral therapy is a key to controlling HIV infection. Late diagnosis and presentation to care diminish the benefits of antiretrovirals and increase risk of transmission. We aimed to identify late presenters in patients sent for first CD4 T cell count after HIV diagnosis, for therapy initiation evaluation. Further we aimed at identifying patient factors associated with higher risk of late presentation. Methods: Retrospective data collection and analysis was done for 3680 subjects visiting the laboratory for CD4 T cell counts between 2001 and 2007. We segregated the patients on basis of their CD4 T cell counts after first HIV diagnosis. Factors associated with risk of late presentation to CD4 T cell counts after HIV diagnosis were identified using univariate analysis, and the strength of association of individual factor was assessed by calculation of odds ratios. Results: Of 3680 subjects, 2936 (83.37%) were defined as late presenters. Late testing varied among age groups, transmission categories, and gender. Males were twice as likely to present late as compared to females. We found significant positive association of heterosexual transmission route (p < 0.001), and older age groups of 45 years and above (p = 0.0004) to late presentation. Female sex, children below 14 years of age and sexual contact with HIV positive spouse were associated with significantly lower risks to presenting late. Intravenous drug users were also associated with lower risks of late presentation, in comparison to heterosexual transmission route. Conclusions: The study identifies HIV infected population groups at a higher risk of late presentation to care and treatment. The risk factors identified to be associated with late presentation should be utilised in formulating targeted public health interventions in order to improve early HIV diagnosis.


Related Articles

  • Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges? Boullie, A.; Ford, N. // Sexually Transmitted Infections;Dec2007, Vol. 83 Issue 8, p503 

    The article comments on the need for cost-effective interventions to reduce HIV in developing countries. There have been concerns on the promotion of widespread access to antiretroviral therapy in Southern Africa. Data on the effectiveness of the interventions since year 2000 have been compiled....

  • Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Kimmel, April D.; Resch, Stephen C.; Anglaret, Xavier; Daniels, Norman; Goldie, Sue J.; Danel, Christine; Wong, Angela Y.; Freedberg, Kenneth A.; Weinstein, Milton C. // Cost Effectiveness & Resource Allocation;2012, Vol. 10 Issue 1, p12 

    Background: In resource-limited settings, HIV budgets are flattening or decreasing. A policy of discontinuing antiretroviral therapy (ART) after HIV treatment failure was modeled to highlight trade-offs among competing policy goals of optimizing individual and population health outcomes....

  • Implementation of a standardized HIV patient monitoring system in Guyana. Halpern, Mina; Lachmansingh, Bendita; Minior, Thomas; Hasbrouck, La Mar; Persaud, Nicholas; Foo, Astrid // Revista Panamericana de Salud Publica;Aug2010, Vol. 28 Issue 2, p107 

    Objective. To describe the process used to implement a comprehensive, standardized, and reliable national system for data collection for HIV care and treatment in Guyana; to provide examples of the program-level data resulting from implementation; and to highlight the monitoring benefits for...

  • The Case for Earlier Treatment of HIV Infection. Holmberg, Scott D.; Palella Jr., Frank J.; Lichtenstein, Kenneth A.; Havlir, Diane V. // Clinical Infectious Diseases;12/1/2004, Vol. 39 Issue 11, p1699 

    Current US guidelines advise that antiretroviral therapy for asymptomatic HIV patients should definitely be started for those who have CD4+ cell counts of >200 cells/μL, but antiretroviral therapy is often not started at CD4+ cell counts much above that level. Guidelines advocating later...

  • The changing epidemiology of prevalent diagnosed HIV infections in England, Wales, and Northern Ireland, 1997 to 2003. Rice, B. D.; Payne, L. J.; Sinka, K.; Patel, B.; Evans, B. G.; Delpech, V. // Sexually Transmitted Infections;Jun2005, Vol. 81 Issue 3, p223 

    Objectives: To present the current epidemiology of prevalent diagnosed HIV infections in England, Wales, and Northern Ireland (E, W, & NI) and describe trends over time. Methods: Descriptive analyses of the annual national Survey of Prevalent HIV Infections Diagnosed...

  • "I will not let my HIV status stand in the way." Decisions on motherhood among women on ART in a slum in Kenya- a qualitative study. Ujiji, Opondo Awiti; Ekström, Anna Mia; Ilako, Festus; Indalo, Dorcas; Rubenson, Birgitta // BMC Women's Health;2010, Vol. 10, p13 

    Background: The African Medical Research Foundation antiretroviral therapy program at the community health centre in Kibera counsels women to wait with pregnancy until they reach the acceptable level of 350 cells/ml CD4 count and to discuss their pregnancy intentions with their health care...

  • Overcoming the False Dichotomy of Curative vs Palliative Care for Late-Stage HIV/AIDS: "Let Me Live the Way I Want to Live, Until I Can't". Selwyn, Peter A.; Forstein, Marshall // JAMA: Journal of the American Medical Association;8/13/2003, Vol. 290 Issue 6, p806 

    Recent advances in human immunodeficiency virus (HIV) therapy have significantly reduced HIV-related mortality in the developed world, but mortality rates have plateaued, and AIDS remains a leading cause of serious illness and death for young adults. The chronic nature of the HIV disease course...

  • Current Management Challenges in HIV: Tolerability of Antiretrovirals and Metabolic Complications. Hicks, Charles; Currier, Judith; Sax, Paul; Sherer, Renslow; Wanke, Christine // AIDS Patient Care & STDs;May2003, Vol. 17 Issue 5, p221 

    The use of antiretroviral therapy for HIV infection has led to substantial reductions in morbidity and mortality. Many regimens, such as those combining three or more antiretroviral agents, result in near-complete suppression of HIV replication. Increased attention to short- and long-term...

  • High Levels of Primary Antiretroviral Resistance Genotypic Mutations And B/F Recombinants in Santos, Brazil. Sucupira, Maria Cecilia Araripe; Caseiro, Marcos Montani; Alves, Katia; Tescarollo, Graziela; Janini, Luiz Mario; Sabino, Ester Cerdeira; Castelo, Adauto; Page-Shafer, Kim; Diaz, Ricardo Sobhie // AIDS Patient Care & STDs;Feb2007, Vol. 21 Issue 2, p116 

    This study characterized HIV-1 among antiretroviral-naïve populations presenting recent infection (RI) or long-standing infection (LSI). Sera collected from January 1999 to December 2001 at an anonymous HIV testing site in Santos, Brazil, were submitted to serologic testing algorithm for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics